Document is current
Any future updates will be listed below
-
Authors
Wall, Sarah A. https://orcid.org/0000-0002-8845-1046
Tamari, Roni https://orcid.org/0000-0002-2386-0850
DeFilipp, Zachariah https://orcid.org/0000-0002-7994-8974
Hobbs, Gabriela S. https://orcid.org/0000-0002-0199-9333
-
Funding
Funding for this research was provided by:
Incyte Corporation (n/a, n/a, n/a, n/a)
- License Information
-
More Information
Article History
Received: 6 November 2024
Accepted: 16 February 2025
First Online: 22 March 2025
Declarations
:
: Not applicable.
: Sarah A. Wall: Received research support from AbbVie, CTI Biopharma, Incyte, and Telios; and is a member of the Sobi Educational Speaker Bureau. Roni Tamari: Reports no conflicts of interest. Zachariah DeFilipp: Received research support from Incyte, RegImmune Corporation, and Taiho Oncology Inc.; and has received consulting fees from Sanofi, Incyte, Inhibrx, PharmaBiome AG, Ono Pharmaceutical, RegImmune Corporation, MaaT Pharma, and Forte Biosciences Inc. Gabriela S. Hobbs: Received honoraria from GSK, BMS, Incyte, Pfizer, PharmaEssentia, Novartis, Sobi, Cogent, and AbbVie. Spouse is employed by Regeneron. Received research support from Incyte and Bayer.
